• Creabilis SA, of Luxembourg, said it treated the first patients in its Phase IIb study of lead product CT327, a TrkA kinase inhibitor, in patients with atopic dermatitis. The study is enrolling 210 adult and adolescent patients with mild to moderate atopic dermatitis and at least moderate pruritis, with the primary endpoint designed to assess pruritis using a visual analogue scale and control of disease determined by Investigator Global Assessment. Quality of life measures also will be analyzed. Results are anticipated in the second quarter of 2014.

• GW Pharmaceuticals plc, of London, said it started a Phase I trial of GWP42006, a nonpsychoactive cannabinoid, for the treatment of epilepsy. According to clinicaltrials.gov, the study will enroll healthy volunteers, with a primary objective of evaluating safety and tolerability of single-ascending and multiple doses of GWP42006 vs. placebo.

• Medivir AB, of Huddinge, Sweden, signed a license agreement with Grupo Ferrer International SA, of Barcelona, Spain, for commercialization of Adasuve (Staccato loxapine) in the Nordic region. Adasuve is approved in Europe for mild to moderate agitation of patients with schizophrenia or bipolar disease. Under the agreement, Ferrer will give Medivir rights to promote, market, sell and distribute Adasuve in countries including Denmark, Finland, Norway, Iceland and Sweden. Medivir will be the exclusive supplier of the drug in those regions. In return, it will pay make an up-front payment to Ferrer, plus milestone payments on cumulative sales performance.

• Viralytics Ltd., of Sydney, said that its Phase II trial of Cavatak (coxsackievirus A21) for late-stage melanoma met its primary endpoint of immune-related progression free survival (irPFS) at six months after the first dose. The study aims to enroll 54 patients with late stage (IIIc and IV) malignant melanoma. The goal was to observe 10 patients out of 54 reporting irPFS at six months, and that was achieved after evaluating only 30 patients, with an irPFS rate of 33 percent. There are now 44 patients enrolled, with full enrollment expected by the end of 2013.